Autonomic Technologies Appoints Niamh Pellegrini as President and Chief Executive Officer

REDWOOD CITY, CA--(Marketwired - Apr 13, 2016) - Autonomic Technologies, Inc. (ATI) today announced the appointment of Niamh Pellegrini to the position of President and Chief Executive Officer and member of its board of directors. In this role, Ms. Pellegrini will lead the company's efforts to bring innovative therapies to physicians and their patients who suffer from severe and disabling headaches.

Ms. Pellegrini has over twenty-five years of experience in the healthcare industry including a broad range of operational, strategic and commercial leadership positions. Most recently, Ms. Pellegrini held the position of President, North America at Thoratec, a leader in implantable mechanical circulatory support therapies. Previously, Ms. Pellegrini held senior sales, marketing, business development and general management positions across a number of business units of Johnson and Johnson, including Acclarent and LifeScan.

Additionally, the company has announced that Gerhard Burbach, former CEO of Thoratec and currently an independent board member of ATI, has been appointed Chairman of the Board.

"Niamh brings an impressive track record of driving growth in multinational medical device businesses where she has consistently built and maintained leading market positions," said Mr. Burbach. "We are pleased to have such an accomplished executive join ATI at this important point in the company's development, and we look forward to strong commercial and clinical success under her very capable leadership."

"It is an exciting time to join ATI as we expand our commercial presence in Europe and accelerate our US clinical trial. The published clinical results for the Pulsante® Microstimulator are compelling and demonstrate that we truly can improve the quality of life for many patients by freeing them from the pain of disabling headaches."

About Autonomic Technologies

Autonomic Technologies, Inc. (ATI®) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante® Microstimulator, is CE marked in Europe for the treatment of cluster headache. The device (also known as Autonomic Technologies, Inc. (ATI®) Neurostimulation System) is under an IDE study in the US for the treatment of chronic cluster headache. ATI is backed by world-class European and US investors including Edmond de Rothschild Investment Partners, Forbion Capital Partners, HBM Healthcare Investments, Kleiner Perkins Caufield and Byers, InterWest Partners, Aberdare Ventures, Novartis Venture Funds, Capital Royalty Group and Cleveland Clinic. For more information, please visit: www.pulsante.eu or www.ati-spg.com.